Nalaganje...
Gemtuzumab Ozogamicin for Treatment of Acute Myeloid Leukemia
INTRODUCTION: Gemtuzumab ozogamicin (GO) is an antibody-drug conjugate consisting of a monoclonal antibody targeting CD33 linked to a cytotoxic derivative of calicheamicin. Despite the known clinical efficacy in relapsed/refractory acute myeloid leukemia (AML), GO was withdrawn from the market in 20...
Shranjeno v:
| izdano v: | Expert Rev Clin Pharmacol |
|---|---|
| Main Authors: | , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
2018
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6661897/ https://ncbi.nlm.nih.gov/pubmed/29787320 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/17512433.2018.1478725 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|